The opportunities in these indications can be assessed by deploying effective new product planning / opportunity assessment methodologies, including evaluating the following for each potential indication: Level of in-class / competitive activity Likelihood of technical and regulatory success (i.e., based on scientific rationale and regulatory precedent) Level and nature of unmet needs for new therapies in the disease area of interest Potential for GLP1-s to address these unmet needs Commercial attractiveness of market Potential speed to market Alignment with individual manufacturer portfolio / strategy / capabilities Conclusion Incretin mimetics have had an immense and growing impact on patient outcomes
Under the brand name Victoza, it's approved to treat type 2 diabetes, while under the brand name Saxenda, it's approved for weight loss
Key Takeaways Ozempic, originally created to treat type 2 diabetes, has shown promise as an aid for weight loss and reducing belly fat when used alongside diet and exercise over six weeks
Alcohol use is a common question as well
The patent cliff and beyond: A definitive guide to generic and biosimilar market entry
The gut-cardiovascular connection: New era for cardiovascular therapy [J]
